Bioluminescent evaluation of the therapeutic effects of total body irradiation in a murine hematological malignancy model

Experimental Hematology

Volumn 36, Issue 12, 2008, Pages 1634-1641

  Inoue, Yusuke ^a   Izawa, Kiyoko ^b   Kiryu, Shigeru ^c   Kobayashi, Seiichiro ^b   Tojo, Arinobu ^b   Ohtomo, Kuni ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b THE UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; FIREFLY LUCIFERASE; PROTEIN P190;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BONE MARROW TRANSPLANTATION; CELL COUNT; CELL LINE; CELL SUSPENSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HEMATOLOGIC MALIGNANCY; IN VIVO STUDY; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; WHOLE BODY RADIATION;

ANIMALS; BONE MARROW TRANSPLANTATION; FEMALE; GAMMA RAYS; GENES, ABL; HUMANS; LUCIFERASES, FIREFLY; LUMINESCENT MEASUREMENTS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TRANSPLANTATION, ISOGENEIC; WHOLE-BODY IRRADIATION;

MURINAE; MUS;

EID: 55549132913     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.08.004     Document Type: Article

References (37)

1. Contag C.H., Jenkins D., Contag P.R., and Negrin R.S. Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia 2 (2000) 41-52
2. Edinger M., Cao Y.A., Hornig Y.S., et al. Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur J Cancer 38 (2002) 2128-2136
3. Inoue Y., Izawa K., Tojo A., et al. Monitoring of disease progression by bioluminescence imaging and magnetic resonance imaging in an animal model of hematologic malignancy. Exp Hematol 35 (2007) 407-415
4. Edinger M., Cao Y.A., Verneris M.R., Bachmann M.H., Contag C.H., and Negrin R.S. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 101 (2003) 640-648
5. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
6. Wu K.D., Cho Y.S., Katz J., et al. Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo. Proc Natl Acad Sci U S A 102 (2005) 10640-10645
7. Armstrong S.A., Kung A.L., Mabon M.E., et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3 (2003) 173-183
8. Xin X., Abrams T.J., Hollenbach P.W., et al. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res 12 (2006) 4908-4915
9. Paroo Z., Bollinger R.A., Braasch D.A., et al. Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden. Mol Imaging 3 (2004) 117-124
10. Nogawa M., Yuasa T., Kimura S., et al. Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. Cancer Lett 217 (2005) 243-253
11. Szentirmai O., Baker C.H., Lin N., et al. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 58 (2006) 365-372
12. Smakman N., Martens A., Kranenburg O., and Borel Rinkes I.H. Validation of bioluminescence imaging of colorectal liver metastases in the mouse. J Surg Res 122 (2004) 225-230
13. Mandl S.J., Mari C., Edinger M., et al. Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome. Mol Imaging 3 (2004) 1-8
14. Jenkins D.E., Oei Y., Hornig Y.S., et al. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis 20 (2003) 733-744
15. Scatena C.D., Hepner M.A., Oei Y.A., et al. Imaging of bioluminescent LNCaP-luc-M6 tumors: a new animal model for the study of metastatic human prostate cancer. Prostate 15 59 (2004) 292-303
16. Zeamari S., Rumping G., Floot B., Lyons S., and Stewart F.A. In vivo bioluminescence imaging of locally disseminated colon carcinoma in rats. Br J Cancer 90 (2004) 1259-1264
17. Nyati M.K., Symon Z., Kievit E., et al. The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model. Gene Ther 9 (2002) 844-849
18. Rehemtulla A., Stegman L.D., Cardozo S.J., et al. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2 (2000) 491-495
19. Wissink E.H., Verbrugge I., Vink S.R., et al. TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy. Radiother Oncol 80 (2006) 214-222
20. Lee C.K. Evolving role of radiation therapy for hematologic malignancies. Hematol Oncol Clin North Am 20 (2006) 471-503
21. Kal H.B., Loes van Kempen-Harteveld M., Heijenbrok-Kal M.H., and Struikmans H. Biologically effective dose in total-body irradiation and hematopoietic stem cell transplantation. Strahlenther Onkol 182 (2006) 672-679
22. Gabriel D.A., Shea T.C., Serody J.S., et al. Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies. Biol Blood Marrow Transplant 11 (2005) 1022-1030
23. Nieder C., Licht T., Andratschke N., Peschel C., and Molls M. Influence of differing radiotherapy strategies on treatment results in diffuse large-cell lymphoma: a review. Cancer Treat Rev 29 (2003) 11-19
24. Gustavsson A., Osterman B., and Cavallin-Ståhl E. A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma. Acta Oncol 42 (2003) 605-619
25. Inoue Y., Tojo A., Sekine R., et al. In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals. Eur J Nucl Med Mol Imaging 33 (2006) 557-565
26. Copelan E.A., and McGuire E.A. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 85 (1995) 1151-1168
27. Li S., Ilaria Jr. R.L., Million R.P., Daley G.Q., and Van Etten R.A. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 189 (1999) 1399-1412
28. Baba S., Cho S.Y., Ye Z., Cheng L., Engles J.M., and Wahl R.L. How reproducible is bioluminescent imaging of tumor cell growth? Single time point versus the dynamic measurement approach. Mol Imaging 6 (2007) 315-322
29. Lin C.S., Goldthwait D.A., and Samols D. Induction of transcription from the long terminal repeat of Moloney murine sarcoma provirus by UV-irradiation, x-irradiation, and phorbol ester. Proc Natl Acad Sci U S A 87 (1990) 36-40
30. Cheng X., and Iliakis G. Effect of ionizing radiation on the expression of chloramphenicol acetyltransferase gene under the control of commonly used constitutive or inducible promoters. Int J Radiat Biol 67 (1995) 261-267
31. Faure E., Cavard C., Zider A., Guillet J.P., Resbeut M., and Champion S. X irradiation-induced transcription from the HIV type 1 long terminal repeat. AIDS Res Hum Retroviruses 11 (1995) 41-43
32. Dent P., Yacoub A., and Contessa J. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res 159 (2003) 283-300
33. Chastel C., Jiricny J., and Jaussi R. Activation of stress-responsive promoters by ionizing radiation for deployment in targeted gene therapy. DNA Repair 3 (2004) 201-215
34. Kim S., Lee K., Kim M.D., et al. Factors affecting the performance of different long terminal repeats in the retroviral vector. Biochem Biophys Res Commun 343 (2006) 1017-1022
35. LoSardo J.E., Cupelli L.A., Short M.K., Berman J.W., and Lenz J. Differences in activities of murine retroviral long terminal repeats in cytotoxic T lymphocytes and T-lymphoma cells. J Virol 63 (1989) 1087-1094
36. Svensson R.U., Barnes J.M., and Rokhlin O.W. Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy. Cancer Res 67 (2007) 10445-10454
37. Kim K.I., Kang J.H., Chung J.K., et al. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells. J Nucl Med 48 (2007) 1553-1561